Director, KOL Engagement

Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti-Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X.
*Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners.
Position Overview
Tonix Pharmaceuticals is seeking a Director, KOL Engagement to lead the development and execution of key opinion leader (KOL) engagement strategies supporting TONMYA® and the broader Tonix portfolio.
This role will lead the Thought Leader Liaison (TLL) team, strengthen relationships with key opinion leaders, and collaborate with Marketing, Sales, Medical Affairs, and other cross-functional teams to drive engagement initiatives that align with brand priorities, support commercial objectives, and meet applicable compliance requirements.
Key Responsibilities
KOL Engagement & Thought Leader Leadership
Manage and coach a team of Thought Leader Liaisons (TLLs), supporting field execution, performance, and professional development.
Execute KOL identification, segmentation, prioritization, and engagement plans aligned with commercial objectives.
Build relationships with established and emerging thought leaders; coordinate advisory boards, executive engagements, and insight-generating forums.
Partner with Medical Affairs to coordinate external engagement while maintaining appropriate commercial and medical boundaries.
Capture and translate KOL and field insights into actionable brand and portfolio recommendations.
Speaker Programs & Professional Education
Manage peer-to-peer education and speaker bureau programs, including speaker selection, training, execution, and performance evaluation.
Oversee promotional and educational materials for speaker programs, KOL engagement, and other HCP-facing initiatives.
Use customer needs and program results to refine content, audiences, channels, and engagement approaches.
Partner with Medical Affairs, Regulatory, Legal, and Compliance to ensure scientific accuracy and compliant execution.
Congress Strategy & Commercial Engagement
Manage commercial planning and execution for priority medical congresses and professional meetings.
Develop and implement congress plans covering booth presence, HCP and KOL meetings, product theaters, speaker programs, and advisory boards.
Coordinate with Medical Affairs and cross-functional partners on a cohesive Tonix presence and incorporate congress insights into future plans.
Oversee external agencies and vendors supporting congress programs and execution.
Portfolio Strategy & Operational Leadership
Support professional engagement strategy for TONMYA® (cyclobenzaprine HCl sublingual tablets), approved for the treatment of fibromyalgia in adults, and prepare scalable programs for potential future indications and pipeline assets.
Partner across commercial and development functions to align KOL engagement, education, and congress priorities with brand and portfolio objectives.